Equillium Announces Initiation of Phase 1 study of EQ102, A First-in-Class Multi-Cytokine Inhibitor of IL-15 and IL-21 Targeting Celiac Disease

Press/Media

Period1 Nov 2022 → 2 Nov 2022

Media coverage

12

Media coverage